Addressing Belantamab Mafodotin-Related Corneal Events in Myeloma is Key to Continuing Treatment
December 6th 2019Rakesh Popat, MD, discusses the DREAMM-1 trial and how to manage the corneal adverse events that result from belantamab mafodotin treatment in patients with relapsed/refractory myeloma.
Read More